Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Jan 12, 2024

SELL
$48.48 - $57.85 $27,391 - $32,685
-565 Reduced 2.12%
26,127 $1.34 Million
Q3 2023

Oct 10, 2023

BUY
$57.89 - $64.73 $37,165 - $41,556
642 Added 2.46%
26,692 $1.55 Million
Q2 2023

Jul 10, 2023

BUY
$63.71 - $70.74 $10,193 - $11,318
160 Added 0.62%
26,050 $1.67 Million
Q1 2023

Apr 11, 2023

BUY
$65.71 - $74.53 $5,716 - $6,484
87 Added 0.34%
25,890 $1.79 Million
Q4 2022

Jan 11, 2023

SELL
$68.48 - $81.09 $303,024 - $358,823
-4,425 Reduced 14.64%
25,803 $1.86 Million
Q3 2022

Oct 07, 2022

BUY
$0.13 - $76.84 $204 - $120,869
1,573 Added 5.49%
30,228 $2.15 Million
Q2 2022

Jul 08, 2022

BUY
$72.62 - $79.98 $43,063 - $47,428
593 Added 2.11%
28,655 $2.21 Million
Q1 2022

Apr 14, 2022

BUY
$61.48 - $73.72 $57,545 - $69,001
936 Added 3.45%
28,062 $2.05 Million
Q4 2021

Jan 11, 2022

BUY
$53.63 - $62.52 $25,420 - $29,634
474 Added 1.78%
27,126 $1.69 Million
Q3 2021

Oct 13, 2021

BUY
$59.17 - $69.31 $30,354 - $35,556
513 Added 1.96%
26,652 $1.58 Million
Q2 2021

Jul 15, 2021

BUY
$61.91 - $67.42 $13,372 - $14,562
216 Added 0.83%
26,139 $1.75 Million
Q1 2021

Apr 09, 2021

SELL
$59.34 - $66.74 $9,791 - $11,012
-165 Reduced 0.63%
25,923 $1.64 Million
Q4 2020

Jan 11, 2021

BUY
$57.74 - $65.43 $28,003 - $31,733
485 Added 1.89%
26,088 $1.62 Million
Q3 2020

Oct 08, 2020

SELL
$57.43 - $63.64 $243,216 - $269,515
-4,235 Reduced 14.19%
25,603 $1.54 Million
Q2 2020

Jul 09, 2020

SELL
$54.82 - $64.09 $110,462 - $129,141
-2,015 Reduced 6.33%
29,838 $1.75 Million
Q1 2020

Apr 14, 2020

BUY
$46.4 - $67.43 $1.48 Million - $2.15 Million
31,853 New
31,853 $1.78 Million

Others Institutions Holding BMY

About BRISTOL MYERS SQUIBB CO


  • Ticker BMY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,126,160,000
  • Market Cap $113B
  • Description
  • Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...
More about BMY
Track This Portfolio

Track Stolper CO Portfolio

Follow Stolper CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Stolper CO, based on Form 13F filings with the SEC.

News

Stay updated on Stolper CO with notifications on news.